Due to the inherent effects of SGLT2 inhibitors such as anti-inflammatory effects and cellular protection, there was an expectation that SGLT2 inhibitors may improve the clinical course of COVID-19 patients. The gene discussed is SLC5A2; the disease is COVID-19.